About Dynavax Technologies (NASDAQ:DVAX)
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company's lead product candidates include HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of the virus in adults age 18 years and older; SD-101, a cancer immunotherapy that is in Phase 2 clinical studies; and DV281, an investigational TLR9 agonist for the treatment of non-small cell lung cancer. Its product candidates also comprise AZD1419, which is in Phase II clinical trial for the treatment of asthma; DV230F that is in preclinical stage for the treatment of liver tumors; and DV1001, a TLR 7&8 agonist, which is in preclinical stage for oncology. It has collaboration and license agreements with AstraZeneca AB to develop AZD1419 for the treatment of asthma; and Merck & Co. to develop SD-101 for various immuno-oncology therapies. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is headquartered in Berkeley, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:DVAX
CUSIP26815810
Phone510-848-5100
Debt
Debt-to-Equity RatioN/A
Current Ratio10.65%
Quick Ratio10.64%
Price-To-Earnings
Trailing P/E Ratio-10.66
Forward P/E Ratio-9.66
P/E GrowthN/A
Sales & Book Value
Annual Sales$330,000.00
Price / Sales3,448.47
Cash FlowN/A
Price / CashN/A
Book Value$3.29 per share
Price / Book5.61
Profitability
EPS (Most Recent Fiscal Year)($1.73)
Net Income$-95,150,000.00
Net Margins-29,099.08%
Return on Equity-57.43%
Return on Assets-52.76%
Miscellaneous
Employees170
Outstanding Shares61,680,000
Dynavax Technologies (NASDAQ:DVAX) Frequently Asked Questions
What is Dynavax Technologies' stock symbol?
Dynavax Technologies trades on the NASDAQ under the ticker symbol "DVAX."
How were Dynavax Technologies' earnings last quarter?
Dynavax Technologies (NASDAQ:DVAX) posted its quarterly earnings data on Thursday, March, 8th. The biopharmaceutical company reported ($0.43) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by $0.32. The biopharmaceutical company earned $0.02 million during the quarter, compared to analysts' expectations of $0.53 million. Dynavax Technologies had a negative net margin of 29,099.08% and a negative return on equity of 57.43%. View Dynavax Technologies' Earnings History.
When is Dynavax Technologies' next earnings date?
What price target have analysts set for DVAX?
5 brokerages have issued 1 year target prices for Dynavax Technologies' shares. Their forecasts range from $25.00 to $30.00. On average, they anticipate Dynavax Technologies' stock price to reach $27.40 in the next year. View Analyst Ratings for Dynavax Technologies.
What are Wall Street analysts saying about Dynavax Technologies stock?
Here are some recent quotes from research analysts about Dynavax Technologies stock:
- 1. Cantor Fitzgerald analysts commented, "HEPLISAV-B Launched. Dynavax reported HEPLISAV-B, a two-dose hepatitis B vaccine, has been launched in the U.S. with a 60-person field sales team (over previous 50-person estimate) covering 75% of the market. HEPLISAV-B was recommended by the CDC for use in the vaccination of adults, which the company believes is critical to drive broad insurance coverage and adoption. As previously reported, the company has a drug supply of over 250,000 vials, with an additional 750,000 vials worth of raw material. We believe this is supply is sufficient for over two years." (3/8/2018)
- 2. According to Zacks Investment Research, "Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax's clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. " (1/10/2018)
- 3. Cowen Inc analysts commented, "Dynavax reported a Q3 net loss of $22.1MM and ended the quarter with $192MM in." (11/3/2017)
Who are some of Dynavax Technologies' key competitors?
Some companies that are related to Dynavax Technologies include Hutchison China MediTech (HCM), Taro Pharmaceutical Industries (TARO), Loxo Oncology (LOXO), FibroGen (FGEN), GW Pharmaceuticals (GWPH), Advanced Accelerator Application (AAAP), Blueprint Medicines (BPMC), Ligand Pharmaceuticals (LGND), Array BioPharma (ARRY), Tesaro (TSRO), Ultragenyx Pharmaceutical (RARE), Emergent BioSolutions (EBS), Amicus Therapeutics (FOLD), Ascendis Pharma (ASND) and Evotec A.G. (EVTCY).
Who are Dynavax Technologies' key executives?
Dynavax Technologies' management team includes the folowing people:
- Mr. Eddie Gray, CEO & Director (Age 59)
- Dr. Dennis A. Carson, Co-Founder & Director (Age 71)
- Mr. Michael S. Ostrach, CFO, Chief Bus. Officer & Sr. VP (Age 66)
- Mr. David F. Novack, Sr. VP of Operations and Quality (Age 56)
- Dr. Robert L. Coffman, Chief Scientific Officer and Sr. VP (Age 71)
Has Dynavax Technologies been receiving favorable news coverage?
Media stories about DVAX stock have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Dynavax Technologies earned a media sentiment score of 0.22 on Accern's scale. They also assigned media coverage about the biopharmaceutical company an impact score of 45.94 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.
How do I buy shares of Dynavax Technologies?
Shares of DVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Dynavax Technologies' stock price today?
One share of DVAX stock can currently be purchased for approximately $18.45.
How big of a company is Dynavax Technologies?
Dynavax Technologies has a market capitalization of $1.11 billion and generates $330,000.00 in revenue each year. The biopharmaceutical company earns $-95,150,000.00 in net income (profit) each year or ($1.73) on an earnings per share basis. Dynavax Technologies employs 170 workers across the globe.
How can I contact Dynavax Technologies?
Dynavax Technologies' mailing address is 2929 SEVENTH STREET SUITE 100, BERKELEY CA, 94710. The biopharmaceutical company can be reached via phone at 510-848-5100 or via email at [email protected]
MarketBeat Community Rating for Dynavax Technologies (DVAX)
MarketBeat's community ratings are surveys of what our community members think about Dynavax Technologies and other stocks. Vote "Outperform" if you believe DVAX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DVAX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Dynavax Technologies (NASDAQ:DVAX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
5 Wall Street analysts have issued ratings and price targets for Dynavax Technologies in the last 12 months. Their average twelve-month price target is $27.40, suggesting that the stock has a possible upside of 48.51%. The high price target for DVAX is $30.00 and the low price target for DVAX is $25.00. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.80 | 2.80 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $27.40 | $27.40 | $28.00 | $27.80 |
| Price Target Upside: | 48.51% upside | 52.22% upside | 39.65% upside | 35.61% upside |
Dynavax Technologies (NASDAQ:DVAX) Consensus Price Target History
Dynavax Technologies (NASDAQ:DVAX) Analyst Ratings History
Show:
(Data available from 4/24/2016 forward)
Dynavax Technologies (NASDAQ:DVAX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Dynavax Technologies (NASDAQ DVAX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 2.90%
Institutional Ownership Percentage: 71.44%
Dynavax Technologies (NASDAQ DVAX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/15/2018 | David F Novack | Insider | Sell | 16,109 | $16.30 | $262,576.70 | |  |
| 3/13/2018 | David F Novack | Insider | Sell | 34,214 | $16.52 | $565,215.28 | 21,613 | |
| 3/9/2018 | David F Novack | Insider | Sell | 2,121 | $17.97 | $38,114.37 | 77,192 | |
| 1/4/2018 | David Louis Johnson | VP | Sell | 3,092 | $18.60 | $57,511.20 | 7,780 | |
| 12/13/2017 | Robert Coffman | Insider | Sell | 7,500 | $18.90 | $141,750.00 | | |
| 1/24/2017 | Robert Janssen | VP | Buy | 6,000 | $4.04 | $24,240.00 | 12,048 | |
| 6/28/2016 | Robert Janssen | VP | Buy | 1,452 | $13.68 | $19,863.36 | 6,048 | |
| 5/20/2016 | Eddie Gray | CEO | Buy | 2,750 | $15.57 | $42,817.50 | 5,050 | |
| 5/12/2016 | Robert Janssen | VP | Buy | 1,000 | $15.12 | $15,120.00 | 1,000 | |
| 8/14/2014 | Eddie Gray | CEO | Buy | 25,000 | $1.49 | $37,250.00 | | |
| 10/30/2013 | Peggy V Phillips | Director | Buy | 93,023 | $1.08 | $100,464.84 | | |
| 9/14/2012 | Jennifer Lew | VP | Sell | 18,750 | $4.53 | $84,937.50 | | |
| 9/13/2012 | Robert Coffman | VP | Sell | 8,000 | $4.52 | $36,160.00 | | |
(Data available from 1/1/2013 forward)
Dynavax Technologies (NASDAQ DVAX) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Dynavax’s HEPLISAV-B ACIP recommendations published in the CDC’s MMWR
seekingalpha.com - April 23 at 9:29 AM |
 | Dynavax’s HEPLISAV-B® ACIP Recommendations Published in the CDC’s Morbidity and Mortality Weekly Report
finance.yahoo.com - April 23 at 9:29 AM |
 | Dynavax Technologies (DVAX) Cut to "Hold" at BidaskClub
www.americanbankingnews.com - April 22 at 6:46 AM |
| $820,000.00 in Sales Expected for Dynavax Technologies Co. (DVAX) This Quarter
www.americanbankingnews.com - April 20 at 4:25 AM |
 | Pre-Open Stock Movers 04/16: (ERI) (ALKS) (DVAX) Higher; (CLDX) (ALGT) (NLNK) Lower (more...)
www.streetinsider.com - April 18 at 4:40 PM |
| -$0.51 EPS Expected for Dynavax Technologies Co. (DVAX) This Quarter
www.americanbankingnews.com - April 18 at 9:35 AM |
| Dynavax: Positive Results, Market Confusion
seekingalpha.com - April 18 at 9:27 AM |
| Brokers Issue Forecasts for Dynavax Technologies Co.'s Q1 2019 Earnings (DVAX)
www.americanbankingnews.com - April 18 at 8:42 AM |
| Dynavax Provides New Durability of Response Data for SD-101 in Combination with KEYTRUDA® (pembrolizumab) in Melanoma at the 2018 American Association for Cancer Research Annual Meeting
finance.yahoo.com - April 17 at 9:19 AM |
| Dynavax Technologies (DVAX) Given a $27.00 Price Target by Cantor Fitzgerald Analysts
www.americanbankingnews.com - April 16 at 6:30 PM |
| Investors bullish on early-stage data on Dynavax's SD-101 + Keytruda in advanced melanoma; shares up 14% premarket
seekingalpha.com - April 16 at 9:34 AM |
| Dynavax shares rise 14% on promising cancer conference data
finance.yahoo.com - April 16 at 9:34 AM |
| Dynavax Technologies (DVAX) Rating Increased to Buy at BidaskClub
www.americanbankingnews.com - April 16 at 7:00 AM |
| Dynavax Technologies (DVAX) PT Set at $7.00 by Royal Bank of Canada
www.americanbankingnews.com - April 15 at 5:39 PM |
| Dynavax Technologies (DVAX) Upgraded to "Outperform" by Royal Bank of Canada
www.americanbankingnews.com - April 15 at 9:45 AM |
| Dynavax Technologies (DVAX) Rating Increased to Overweight at JPMorgan Chase
www.americanbankingnews.com - April 15 at 9:43 AM |
| Investors Buy High Volume of Put Options on Dynavax Technologies (DVAX)
www.americanbankingnews.com - April 12 at 7:01 AM |
| Dynavax Technologies' (DVAX) "Outperform" Rating Reaffirmed at Cowen
www.americanbankingnews.com - April 11 at 5:01 PM |
| Dynavax Technologies (DVAX) Rating Lowered to Hold at BidaskClub
www.americanbankingnews.com - April 10 at 10:24 AM |
| Dynavax Technologies Co. (DVAX) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - April 7 at 1:29 AM |
| Watch These April Biotech Catalysts
seekingalpha.com - April 3 at 9:10 AM |
| Dynavax Technologies Co. (DVAX) Expected to Post Earnings of -$0.51 Per Share
www.americanbankingnews.com - April 1 at 7:22 AM |
| Dynavax Technologies (DVAX) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - March 28 at 9:49 PM |
| What Are Analysts Saying About The Future Of Dynavax Technologies Corporation’s (NASDAQ:DVAX)?
finance.yahoo.com - March 28 at 8:59 AM |
| Dynavax Technologies (DVAX) Raised to Buy at BidaskClub
www.americanbankingnews.com - March 27 at 5:10 PM |
| Dynavax Technologies (DVAX) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - March 27 at 10:01 AM |
| Dynavax Technologies (DVAX) Raised to "Hold" at BidaskClub
www.americanbankingnews.com - March 25 at 3:12 PM |
| Reviewing Dynavax Technologies (DVAX) and Strongbridge Biopharma (SBBP)
www.americanbankingnews.com - March 24 at 1:49 PM |
| Dynavax Announces Acceptance of Two Data Abstracts for SD-101 in Combination with KEYTRUDA® for Presentation at the 2018 American Association for Cancer Research (AACR) Annual Meeting
finance.yahoo.com - March 23 at 8:54 AM |
| Sonoma Pharmaceuticals (SNOA) versus Dynavax Technologies (DVAX) Financial Survey
www.americanbankingnews.com - March 17 at 9:48 AM |
| Zacks: Analysts Expect Dynavax Technologies Co. (DVAX) Will Post Quarterly Sales of $820,000.00
www.americanbankingnews.com - March 17 at 9:01 AM |
| Insider Selling: Dynavax Technologies Co. (DVAX) Insider Sells 16,109 Shares of Stock
www.americanbankingnews.com - March 16 at 8:14 PM |
| Insider Selling: Dynavax Technologies Co. (DVAX) Insider Sells 34,214 Shares of Stock
www.americanbankingnews.com - March 15 at 10:08 PM |
| Cantor Fitzgerald Weighs in on Dynavax Technologies Co.'s FY2018 Earnings (DVAX)
www.americanbankingnews.com - March 14 at 10:06 AM |
| David F. Novack Sells 2,121 Shares of Dynavax Technologies Co. (DVAX) Stock
www.americanbankingnews.com - March 13 at 8:51 PM |
| Dynavax Technologies Co. (DVAX) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - March 13 at 1:46 AM |
| Dynavax Technologies (DVAX) Given "Buy" Rating at Royal Bank of Canada
www.americanbankingnews.com - March 10 at 4:20 PM |
| Dynavax Technologies (DVAX) Announces Earnings Results
www.americanbankingnews.com - March 9 at 2:03 PM |
| Dynavax Technologies' (DVAX) Buy Rating Reaffirmed at Cantor Fitzgerald
www.americanbankingnews.com - March 8 at 7:03 PM |
| Dynavax Reports Fourth Quarter and Year End 2017 Financial Results
finance.yahoo.com - March 8 at 10:21 AM |
| Dynavax to Present at the Cowen & Co. Annual Health Care Conference
finance.yahoo.com - March 5 at 4:50 PM |
| Dynavax Technologies Co. (DVAX) Position Lifted by State of Wisconsin Investment Board
www.americanbankingnews.com - March 5 at 9:43 AM |
| Dynavax Technologies (DVAX) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - March 5 at 2:16 AM |
| Senvest Management LLC Purchases 349,288 Shares of Dynavax Technologies Co. (DVAX)
www.americanbankingnews.com - February 26 at 12:44 PM |
| Dynavax Technologies Co. (DVAX) to Post Q1 2018 Earnings of ($0.47) Per Share, William Blair Forecasts
www.americanbankingnews.com - February 26 at 2:58 AM |
| Your Daily Pharma Scoop: Dynavax Achieves Major Milestone, GW Pharmaceuticals GWP42006 Fails, Sangamo Signs Deal With Gilead's Kite Unit
seekingalpha.com - February 23 at 9:18 AM |
| Dynavax Technologies (DVAX) Receives "Buy" Rating from Cowen
www.americanbankingnews.com - February 21 at 8:16 PM |
| Dynavax (DVAX) HEPLISAV-B Recommended by CDC Advisory Committee on Immunization Practices for Prevention of Hepatitis B in Adults
www.streetinsider.com - February 21 at 4:55 PM |
 | Dynavax Pops With CDC Recommendation
www.msn.com - February 21 at 4:55 PM |
| Dynavax stock rises after hepatitis B vaccine recommendation by CDC immunization committee
finance.yahoo.com - February 21 at 4:55 PM |
Dynavax Technologies (NASDAQ:DVAX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Dynavax Technologies (NASDAQ:DVAX) Income Statement, Balance Sheet and Cash Flow Statement
Dynavax Technologies (NASDAQ DVAX) Stock Chart for Tuesday, April, 24, 2018
Loading chart…
